ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 141,46
-0,67%
Dow Jones
39 872,99
0,17%
DAX
18 726,76
-0,21%
Brent Oil
82,385
-0,07%
Bitcoin
70 119,99
-0,02%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Genelux Corporation (GNLX)

  7. Genelux Corporation (GNLX) Actualités

GNLX

Genelux (GNLX)

Genelux Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:GNLX
DateHeureSourceTitreSymboleSociété
15/05/202423h59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNLXGenelux Corporation
09/05/202422h25GlobeNewswire Inc.Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business UpdatesNASDAQ:GNLXGenelux Corporation
09/05/202422h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GNLXGenelux Corporation
01/04/202413h00GlobeNewswire Inc.Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:GNLXGenelux Corporation
14/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GNLXGenelux Corporation
05/02/202415h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNLXGenelux Corporation
02/02/202422h36Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:GNLXGenelux Corporation
02/02/202422h06Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:GNLXGenelux Corporation
15/12/202322h08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GNLXGenelux Corporation
27/11/202313h00GlobeNewswire Inc.Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian CancerNASDAQ:GNLXGenelux Corporation
14/11/202323h50GlobeNewswire Inc.Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business UpdatesNASDAQ:GNLXGenelux Corporation
19/09/202323h37Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:GNLXGenelux Corporation
14/09/202313h00GlobeNewswire Inc.Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GNLXGenelux Corporation
14/09/202302h13Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:GNLXGenelux Corporation
07/09/202322h01GlobeNewswire Inc.Genelux Corporation to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:GNLXGenelux Corporation
28/08/202313h00GlobeNewswire Inc.Genelux Corporation Announces New Chief Financial OfficerNASDAQ:GNLXGenelux Corporation
24/08/202322h05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:GNLXGenelux Corporation
14/08/202313h00GlobeNewswire Inc.Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business UpdatesNASDAQ:GNLXGenelux Corporation
02/08/202322h00GlobeNewswire Inc.Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023NASDAQ:GNLXGenelux Corporation
20/07/202322h45GlobeNewswire Inc.Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New HiresNASDAQ:GNLXGenelux Corporation
20/07/202322h15Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:GNLXGenelux Corporation
20/07/202322h05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:GNLXGenelux Corporation
29/06/202313h00GlobeNewswire Inc.Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLCNASDAQ:GNLXGenelux Corporation
29/06/202312h02Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:GNLXGenelux Corporation
22/06/202313h00GlobeNewswire Inc.Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023NASDAQ:GNLXGenelux Corporation
12/06/202313h00GlobeNewswire Inc.Genelux Corporation Announces $18 Million Private PlacementNASDAQ:GNLXGenelux Corporation
12/06/202312h44Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GNLXGenelux Corporation
25/05/202322h01GlobeNewswire Inc.Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) OncNASDAQ:GNLXGenelux Corporation
15/05/202313h00GlobeNewswire Inc.Genelux Corporation Announces $33 Million Private PlacementNASDAQ:GNLXGenelux Corporation
02/05/202322h33Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GNLXGenelux Corporation
 Showing the most relevant articles for your search:NASDAQ:GNLX

Dernières Valeurs Consultées

BIT
2SZM
Graniteshares 2x Short Z...
LSE
83HT
Canary C2
BITMOT
791411
Allian F Ii Tf 1,375% Ap...
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés